Drug Label Explorer

Ken Brown, Agi Kajanaku, Leo Landau, Sam Negassi, Ky Nguyen

Overview



Today we're going to talk about:

- 1. Defining the Problem
- 2. Developing our Solution*
- 3. How does DLE work?
- 4. Next steps!

*DEMO

DRUG LABELS

- Definition: contain critical information on any prescription or over-the-counter
 medication
 - Purpose: to inform healthcare providers of relevant information on dispensing and administering medication to patients

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROPRIETARY NAME safely and effectively. See full prescribing		Highlights of Prescribing Information
nformation for PROPRIETARY NAME. PROPRIETARY NAME (nonproprietary name) dosage form, route of administration, controlled substance symbol nitial U.S. Approval: YYYY	- Toxt (4) - Toxt (4) - WARNINGS AND PRECAUTIONS	
WARNING: TITLE OF WARNING See full prescribing information for complete boxed warning.	 Text (5.x) Text (5.x) 	
• Text (4)	ADVERSE REACTIONS Most common adverse reactions (incidence > x%) are text (6.x) To report SUSPECTED ADVERSE REACTIONS, contact name of manufacturer at toll-free phone # or FDA at 1-800-FDA-1088 or www.fda.aov/med/watch.	
• Text (5.x)		
RECENT MAJOR CHANGES Section Title, Subsection Title (x.x) MYYYY		TERACTIONS
Section Title, Subsection Title (x.x) MYYYY	• Text (7.x) • Text (7.x)	
PROPRIETARY NAME is a (insert FDA established pharmacologic lass text phrase) indicated for (1) imitations of Use [ext (1)	Toxt (8.x) Toxt (8.x) Toxt (8.x) Toxt (8.x) Toxt (8.x)	
	See 17 for PATIENT COUNSEL	ING INFORMATION and
Text (2.x) Text (2.x)	FDA-approved patient labeling	OR and Medication Guide. Revised: M/YYYY
FULL PRESCRIBING INFORMATION: CONTENTS*		
WARNING: TITLE OF WARNING I INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Subsection Title	9 DRUG ABUSE AND DEPENT 9.1 Controlled Substance 9.2 Abuse	Table of Contents
2.2 Subsection Title	9.3 Dependence 10 OVERDOSAGE	
B DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS	11 DESCRIPTION 12 CLINICAL PHARMACOLOGY	
WARNINGS AND PRECAUTIONS	12.1 Mechanism of Action	
5.1 Subsection Title 5.2 Subsection Title	12.2 Pharmacodynamics 12.3 Pharmacokinetics	
6.1 Clinical Trials Experience	12.4 Microticlogy 12.5 Pharmacogenomics	
6.2 Immunopenigity	13 NONCLINICAL TOXICOLOGY	
6.2 or 6.3 Postmarketing Experience P DRUG INTERACTIONS	 Carcinogenesis, Mutagenesis, Impairment of Fertility 	
7.1 Subsection Title 7.2 Subsection Title	13.2 Animal Toxicology and/or Pharmacelogy 14 CUNICAL STUDIES	
USE IN SPECIFIC POPULATIONS	14.1 Subsection Title	
8.1 Pregnancy 8.2 Lactation (if not required to be in PLLR format use Labor and	14.2 Subsection Title 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING	
Delivery) 8.3 Females and Males of Reproductive Potential (if not required		
to be in PLLR format use Nursing Mothers)	17 PATIENT COUNSELING INF * Sections or subsections omitted	
8.4 Pediatric Use 8.5 Geriatric Use	information are not listed.	from the rull prescribing
8.6 Subpopulation X		
FULL PRESCRIBING INFORMATION		Full Prescribing
WARNING: TITLE OF WARNING		Information
Text [see Contraindications (4)]		
Text [see Warnings and Precautions (5.x)] I INDICATIONS AND USAGE		
PROPRIETARY NAME is indicated for		
<u>_imitations of Use</u> Text		
2 DOSAGE AND ADMINISTRATION		
2.1 Subsection Title (e.g., Recommended Dosa	ge)	
2.2 Subsection Title (e.g., Administration Instru	ictions)	
B DOSAGE FORMS AND STRENGTHS Dosage form #1: strength(s) Dosage form #2: strength(s)		
CONTRAINDICATIONS	ate 2	

DRUG LABEL USERS



PHARMACEUTICAL COMPANIES

Regulatory affairs, operations, compliance, labelling, medical affairs, etc



ACADEMIC RESEARCHERS

Life sciences, medical, interdisciplinary, public health



PUBLIC HEALTH SPECIALISTS

Scientists, compliance specialists, epidemiologists

DRUG LABEL USE CASES



Improve decision-making process in developing custom labels

Case Studies


DRUG LABEL CHALLENGES

Lack of discoverability

Multiple sources

Too manual and tedious

Storage of custom labels



DLE


Our site

Demo

https://youtu.be/t8XdRJmkTL0


- Drug Label Search
- Data: EMA & FDA
- Comparisons
- History
- My Labels
- Content Shareable (via direct links)





Methods

How 5 strangers built this in 4 months






Line item deliverables

Agile Framework

- 665 estimated hours of work
- 10 Functional Areas
- 9 Week-long Sprints
- Gitlab Task Tracking
- 1, 2, and then 3 synchronous meetings weekly
- Retrospective after Milestones




Estimates




Most estimates were very close to actual amount of time needed


Largest amount of unplanned work came from emergent feature requests

Architecture









Future

What's next for DLE?

Transfer of ownership

 App is templatized via CloudFormation



 Client can deploy to private Pfizer cloud



Potential improvements

MedDRA ontology

 BERT Model (ML for NLP)

Dedicated Semantic
 Search









you so much!

Questions?

